We are pleased to announce that Jennifer Che, Managing Director of Eagle IP, will be attending the American Intellectual Property Law Association (AIPLA) 2026 Spring Meeting. She will also be participating as a speaker at the AIPLA Chemical Patent Practice Institute, presenting on the China perspective at an international panel on written description. The Chemical Patent Practice Institute will take place from May 11 to 12, while the Spring Meeting will take place from May 13 to 15, 2026, at the historic Fairmont San Francisco.

As one of the most significant gatherings for intellectual property professionals in North America, the AIPLA Spring Meeting is a hub for high-level discussion on the legislative and judicial trends shaping the future of IP. This year's program highlights the intersection of innovation and technology, with a deep focus on "The Future of IP in an AI-Driven World."

If you or your firm will be in San Francisco for AIPLA2026, Jennifer would be delighted to meet to discuss cross-border patent strategies or our specialized services in China. Please reach out to us to schedule a meeting during the conference.

Our Past Events

Recommended Insights

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

12 December 2023
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]

How a Secondhand Ground Brush Wiped Away a Chinese Patent

4 December 2024
A Chinese robot vacuum company digs up “hidden evidence” to successfully invalidate a patent owned by its biggest competitor.  Highlights Background  With the growth of online shopping, it is easier than ever to provide evidence of a sale when the product is still being sold on the market. But what if the product is no […]

What Microsoft’s Recent Patent Invalidation Case in China Teaches Us About User Interface Patents

29 January 2026
Each year the CNIPA publishes its Top Ten Patent Re-examination and Invalidation Cases for the previous year. These cases are meant to be guiding cases, showcasing exemplary real-world decisions that clarify certain aspects of the law. Today we’ll be sharing about one of the Top 10 Invalidation Cases in 2024 involving Microsoft (China) Co., Ltd. […]

Thin Disclosure but "Bulletproof" Protection: How a Salt Form Patent was Upheld in China Despite Minimal Data

8 January 2026
In China, innovative drug companies typically rely on their initial composition of matter patents to block out competitors. Other “follow-on” IP, such as those directed towards formulations, polymorphs, and salt forms, are often regarded as less likely to survive invalidation challenges, especially in China where the standard of “person skilled in the art” is so […]
Top crossarrow-right